Nxera Pharma Co., Ltd.
Nxera Pharma Co., Ltd. (JPX: 4565) is trading at ¥1,225.00, about ₹746 at today's JPY/INR rate, as of 28 Sep 2026, 2:30 AM ET, down 2.78% today. Indian residents can buy Nxera Pharma from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
¥1,190.00
Today's high
¥1,264.00
52 week low
¥723.00
52 week high
¥1,319.00
4565 opened at ¥1,264.00, closed previously at ¥1,260.00, and has traded between ¥723.00 and ¥1,319.00 over the past 52 weeks.
About
Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of pharmaceutical solutions. The company's operations extend across multiple international markets, including Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its array of commercially available products encompasses respiratory treatments like Ultibro/Breezhaler and Seebri/Breezhaler for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler to manage asthma. Other marketed therapeutics include ORAVI, a unique formulation addressing oropharyngeal candidiasis, and PIVLAZ, prescribed for cerebral vasospasm. The firm boasts a robust pipeline of investigational medicines, featuring HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia, Daridorexant targeting insomnia, and HTL0016878 for both schizophrenia and other neuropsychiatric conditions. Additional compounds under development include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, and PF-06954522 for metabolic disorders. The pipeline also contains NBI-1117569 for various neurological diseases and NBI-1117570 for central nervous system ailments. Furthermore, Nxera Pharma is advancing a GPR35 agonist in the preclinical stage for inflammatory bowel disease and other gastrointestinal conditions, alongside other early-stage drug candidates. The company maintains significant strategic collaborations with industry leaders such as AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily.
Key statistics
Avg. volume
919.04K
Market cap
¥112.37B
P/E Ratio
-14.18
Price-to-sales ratio
3.36
Enterprise value
¥149.03B
Free cash flow yield
0.24%
Debt-to-equity ratio
0.84
Return on equity
-12.23%
ROIC
-1.39%
Beta
0.23
Dividend yield
0.00%
Last dividend
¥0.00
Financial overview
Revenue
¥29.61B
Earnings per share
-¥138.80
Free cash flow
-¥3.12B
Net profit margin
-23.34%
Gross margin
76.05%
EBITDA
-¥3.91B
Revenue growth
2.71%
Similar securities
This is not an investment recommendation
How to buy Nxera Pharma from India
Indian residents can buy Nxera Pharma shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to JPY.
Search for Nxera Pharma and place an order
Find Nxera Pharma by name or by its ticker, 4565, and choose an order type. The Tokyo Stock Exchange typically trades in units of 100 shares. Nxera Pharma trades 5:30 am – 12:00 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Nxera Pharma position in JPY and INR. Nxera Pharma pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Nxera Pharma from India
Trading and taxes when buying Nxera Pharma from India
Trading and limits
- Trading hours
- 9:00 am – 3:30 pm JST
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneNxera Pharma does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- Estate or inheritance tax
- May applyJapan levies inheritance tax on Japan-located assets such as direct stocks, with an exemption of ¥30 million plus ¥6 million per statutory heir.Estate tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Nxera Pharma stock?
Yes. Nxera Pharma (4565) has been listed on the Tokyo Stock Exchange since 2004, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to JPY. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Nxera Pharma share cost in rupees?
One Nxera Pharma share is ¥1,225.00 — about ₹746 at a JPY/INR rate of 0.6091 on 27 Sep 2026. Both the Nxera Pharma price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Nxera Pharma from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of Nxera Pharma?
The Tokyo Stock Exchange typically trades in units of 100 shares.
How are gains on Nxera Pharma shares taxed in India?
Japan generally does not levy capital gains tax on non-resident individual investors, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the JPY/INR rate on the purchase and the sale date, so the rupee move counts alongside the Nxera Pharma price. Paasa issues a capital-gains statement for your return.
Does Nxera Pharma pay a dividend?
No. Nxera Pharma does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Nxera Pharma from India?
The Tokyo Stock Exchange trades 5:30 am – 12:00 pm IST in Indian time. It also halts for lunch, 8:00 am – 9:00 am IST. Orders can only execute during that window.
Is there estate or inheritance tax on Nxera Pharma shares held from India?
Japan levies inheritance tax on Japan-located assets such as direct stocks, with an exemption of ¥30 million plus ¥6 million per statutory heir. It applies to your overall holdings in that jurisdiction rather than to any one position.
Do I have to declare Nxera Pharma shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Nxera Pharma holding, its cost and its closing value.
How do I sell Nxera Pharma and bring the money back to India?
You sell during market hours (5:30 am – 12:00 pm IST) and the proceeds settle in JPY in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.